Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

Hematological patients at higher risk of severe COVID‐19 were excluded from the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine trials. In this single‐center observational prospective study (NCT05074706), we evaluate immune response in the hematological patients followed at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossi, Elisa, Aroldi, Andrea, Borin, Lorenza Maria, Verga, Luisa, Fontana, Diletta, Cocito, Federica, Manghisi, Beatrice, Rindone, Giovanni, Cavalca, Fabrizio, Ripamonti, Alessia, Raggi, Monica, Malandrin, Sergio Maria Ivano, Cavallero, Annalisa, Antolini, Laura, Bonardi, Diego, Piazza, Rocco Giovanni, Gambacorti‐Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538646/
https://www.ncbi.nlm.nih.gov/pubmed/36248617
http://dx.doi.org/10.1002/jha2.544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538646/
https://www.ncbi.nlm.nih.gov/pubmed/36248617
http://dx.doi.org/10.1002/jha2.544

Ejemplares similares